RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shin Nippon Biomedical Laboratories - Stock

Shin Nippon Biomedical Laboratories ROCE 2024

Shin Nippon Biomedical Laboratories ROCE

0.12

Ticker

2395.T

ISIN

JP3379950003

WKN

A0BMJN

In 2024, Shin Nippon Biomedical Laboratories's return on capital employed (ROCE) was 0.12, a -43.11% increase from the 0.21 ROCE in the previous year.

Shin Nippon Biomedical Laboratories Aktienanalyse

What does Shin Nippon Biomedical Laboratories do?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Shin Nippon Biomedical Laboratories's Return on Capital Employed (ROCE)

Shin Nippon Biomedical Laboratories's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Shin Nippon Biomedical Laboratories's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Shin Nippon Biomedical Laboratories's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Shin Nippon Biomedical Laboratories’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Shin Nippon Biomedical Laboratories Stock

What is the ROCE (Return on Capital Employed) of Shin Nippon Biomedical Laboratories this year?

The ROCE of Shin Nippon Biomedical Laboratories is 0.12 undefined this year.

How has the ROCE (Return on Capital Employed) of Shin Nippon Biomedical Laboratories developed compared to the previous year?

The ROCE of Shin Nippon Biomedical Laboratories has increased by -43.11% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Shin Nippon Biomedical Laboratories?

A high Return on Capital Employed (ROCE) indicates that Shin Nippon Biomedical Laboratories has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Shin Nippon Biomedical Laboratories?

A low ROCE (Return on Capital Employed) can indicate that Shin Nippon Biomedical Laboratories has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Shin Nippon Biomedical Laboratories impact the company?

An increase in the ROCE of Shin Nippon Biomedical Laboratories can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Shin Nippon Biomedical Laboratories affect the company?

A decrease in ROCE of Shin Nippon Biomedical Laboratories can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Shin Nippon Biomedical Laboratories?

Some factors that can affect Shin Nippon Biomedical Laboratories's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Shin Nippon Biomedical Laboratories so important for investors?

The ROCE of Shin Nippon Biomedical Laboratories is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Shin Nippon Biomedical Laboratories take to improve the ROCE?

To improve the ROCE, Shin Nippon Biomedical Laboratories can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Shin Nippon Biomedical Laboratories pay?

Over the past 12 months, Shin Nippon Biomedical Laboratories paid a dividend of 50 JPY . This corresponds to a dividend yield of about 3.58 %. For the coming 12 months, Shin Nippon Biomedical Laboratories is expected to pay a dividend of 64.31 JPY.

What is the dividend yield of Shin Nippon Biomedical Laboratories?

The current dividend yield of Shin Nippon Biomedical Laboratories is 3.58 %.

When does Shin Nippon Biomedical Laboratories pay dividends?

Shin Nippon Biomedical Laboratories pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories paid dividends every year for the past 9 years.

What is the dividend of Shin Nippon Biomedical Laboratories?

For the upcoming 12 months, dividends amounting to 64.31 JPY are expected. This corresponds to a dividend yield of 4.61 %.

In which sector is Shin Nippon Biomedical Laboratories located?

Shin Nippon Biomedical Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shin Nippon Biomedical Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shin Nippon Biomedical Laboratories from 12/1/2024 amounting to 20 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Shin Nippon Biomedical Laboratories pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Shin Nippon Biomedical Laboratories in the year 2023?

In the year 2023, Shin Nippon Biomedical Laboratories distributed 50 JPY as dividends.

In which currency does Shin Nippon Biomedical Laboratories pay out the dividend?

The dividends of Shin Nippon Biomedical Laboratories are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shin Nippon Biomedical Laboratories

Our stock analysis for Shin Nippon Biomedical Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shin Nippon Biomedical Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.